U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559370) titled 'Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria' on April 23.
Brief Summary: This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Malaria (Plasmodium Falciparum)
Intervention:
DRUG: Artemether/lumefantrine tablets...